1. Comparison of Clinical Outcomes Between Very Long Stents and Overlapping Stents for the Treatment of Diffuse Coronary Disease in Real Clinical Practice
- Author
-
Fernando Lozano-Ruíz-Poveda, José Abellán-Huerta, María T. López-Lluva, Alfonso Jurado-Román, Ignacio Sanchez-Perez, Jesús Piqueras-Flores, Raquel Frías-García, Pedro Pérez-Díaz, Ramón Maseda-Uriza, and Juan Antonio Requena
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Percutaneous ,medicine.medical_treatment ,Myocardial Infarction ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary disease ,Prosthesis Design ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Risk Factors ,Humans ,Medicine ,Fluoroscopy ,Registries ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Adverse effect ,Aged ,Retrospective Studies ,Index Lesion ,medicine.diagnostic_test ,business.industry ,Coronary Thrombosis ,Stent ,General Medicine ,Middle Aged ,equipment and supplies ,medicine.disease ,Clinical Practice ,Treatment Outcome ,surgical procedures, operative ,Retreatment ,Female ,Stents ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
BACKGROUND The stent length as well as the stent overlap for the percutaneous treatment of diffuse coronary disease have been considered predictors of adverse events. However, there are no comparative data on the use of very long stents or overlapping stents in this scenario. OBJECTIVE To compare the clinical results of very long stents (≥40 mm) or overlapping stents in real clinical practice. METHODS We included 643 lesions in 628 consecutive patients treated with a single very long stent (≥40 mm) (251 lesions) or ≥2 overlapped stents (392 lesions). We analyzed the procedural characteristics and the presentation of the combined endpoint [cardiovascular death, non-fatal myocardial infarction, need for target lesion revascularization or stent thrombosis] after a follow-up of 20 months. RESULTS Total stent length was 54 ± 18 mm and minimum diameter was 2.9 ± 1.2 mm. At the end of follow-up, the rate of adverse events was 8.3% (cardiac death: 4.9%, myocardial infarction: 1.7%, target lesion revascularization: 3.1%, stent thrombosis: 0.7%). There were no significant differences between both groups in the presentation of the combined endpoint. Procedures with overlapping stents had more contrast volume (309 ± 115 vs 273 ± 127 ml; p = 0.002), longer duration (47 ± 22 vs 39 ± 18 min; p
- Published
- 2019
- Full Text
- View/download PDF